BioCentury | Dec 19, 2020
Product Development

Dec. 18 Quick Takes: FDA approves expanded label for Benlysta and first oral prostate cancer therapy; plus Novartis, FibroGen, A2i, China’s NRDL and more

...inspection-related conditions, according to the company.Atomwise, FutuRx launch A2iAI drug discovery company Atomwise Inc. and FutuRx...
...funding to develop small molecules for immuno-oncology. The deal represents Atomwise’s second partnership with a global incubator hub. FutuRx...
BioCentury | May 29, 2019
Financial News

How cancer play Pi plans to deploy $19.7M series B

...is not an option because you can’t dose it high enough." Pi was incubated at FutuRx...
...a total of about $24 million to date, including a $2 million seed round from FutuRx...
BioCentury | Feb 22, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

...samples to correlate the target bacteria to the disease. Since its inception in OrbiMed Advisors’ FutuRx...
BioCentury | Feb 20, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

...samples to correlate the target bacteria to the disease. Since its inception in OrbiMed Advisors’ FutuRx...
BioCentury | Jun 7, 2018
Finance

Deerfield goes to school

...considering” umbrella agreements but declined to give details. Silverstein and Gordon pointed to the firm’s FutuRx...
...Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson -- as its closest comparator. FutuRx...
...financial support to companies and positions them for subsequent funding rounds. “A compelling feature of FutuRx...
BioCentury | Feb 9, 2018
Product R&D

Debugging the microbiome

...‘what about trying to take it out?’” said Solomon. Since its inception in OrbiMed Advisors’ FutuRx...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

...research; fund buys institutions' co-investment rights in exchange for a cut of future fund profits FutuRx...
...Takeda Ventures $2.1M base budget per project, up to 85% from OCS, and payment-in-kind consideration FutuRx...
BioCentury | Jun 27, 2017
Financial News

Mitoconix's series A round brings in $20M

...of excess mitochondrial fission that could help prevent Huntington's disease. The company was incubated at FutuRx...
...BioCentury that Takeda sponsored Mochly-Rosen's work at Stanford and recommended the technology for development at FutuRx...
BioCentury | May 26, 2017
Financial News

RM Global raises $30M in first close of new venture fund

...incubator FutuRx Ltd. The fund expects to complete a second closing “in the near future.” FutuRx...
BioCentury | May 19, 2017
Finance

BiomX’s balance

...can select the right time to enter into a strategic relationship." BiomX is housed in FutuRx...
...Innovations, Jan. 16, 2014) . J&J does not have preferential rights to BiomX or any FutuRx...
Items per page:
1 - 10 of 15
BioCentury | Dec 19, 2020
Product Development

Dec. 18 Quick Takes: FDA approves expanded label for Benlysta and first oral prostate cancer therapy; plus Novartis, FibroGen, A2i, China’s NRDL and more

...inspection-related conditions, according to the company.Atomwise, FutuRx launch A2iAI drug discovery company Atomwise Inc. and FutuRx...
...funding to develop small molecules for immuno-oncology. The deal represents Atomwise’s second partnership with a global incubator hub. FutuRx...
BioCentury | May 29, 2019
Financial News

How cancer play Pi plans to deploy $19.7M series B

...is not an option because you can’t dose it high enough." Pi was incubated at FutuRx...
...a total of about $24 million to date, including a $2 million seed round from FutuRx...
BioCentury | Feb 22, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

...samples to correlate the target bacteria to the disease. Since its inception in OrbiMed Advisors’ FutuRx...
BioCentury | Feb 20, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

...samples to correlate the target bacteria to the disease. Since its inception in OrbiMed Advisors’ FutuRx...
BioCentury | Jun 7, 2018
Finance

Deerfield goes to school

...considering” umbrella agreements but declined to give details. Silverstein and Gordon pointed to the firm’s FutuRx...
...Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson -- as its closest comparator. FutuRx...
...financial support to companies and positions them for subsequent funding rounds. “A compelling feature of FutuRx...
BioCentury | Feb 9, 2018
Product R&D

Debugging the microbiome

...‘what about trying to take it out?’” said Solomon. Since its inception in OrbiMed Advisors’ FutuRx...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

...research; fund buys institutions' co-investment rights in exchange for a cut of future fund profits FutuRx...
...Takeda Ventures $2.1M base budget per project, up to 85% from OCS, and payment-in-kind consideration FutuRx...
BioCentury | Jun 27, 2017
Financial News

Mitoconix's series A round brings in $20M

...of excess mitochondrial fission that could help prevent Huntington's disease. The company was incubated at FutuRx...
...BioCentury that Takeda sponsored Mochly-Rosen's work at Stanford and recommended the technology for development at FutuRx...
BioCentury | May 26, 2017
Financial News

RM Global raises $30M in first close of new venture fund

...incubator FutuRx Ltd. The fund expects to complete a second closing “in the near future.” FutuRx...
BioCentury | May 19, 2017
Finance

BiomX’s balance

...can select the right time to enter into a strategic relationship." BiomX is housed in FutuRx...
...Innovations, Jan. 16, 2014) . J&J does not have preferential rights to BiomX or any FutuRx...
Items per page:
1 - 10 of 15